Canada: These 77 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,475

CREON is a drug marketed by

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 15, 2026
Generic Entry Controlled by: Canada Patent 2,619,477

CREON is a drug marketed by

See drug price trends for CREON.

The generic ingredient in CREON is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 20, 2027
Generic Entry Controlled by: Canada Patent 2,677,989

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2026
Generic Entry Controlled by: Canada Patent 2,655,835

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Generic name: carbidopa; levodopa
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 28, 2027
Generic Entry Controlled by: Canada Patent 2,711,014

RYTARY is a drug marketed by Impax. There are eight patents protecting this drug and two Paragraph IV challenges.

This drug has twenty-five patent family members in twelve countries. There has been litigation on patents covering RYTARY

See drug price trends for RYTARY.

The generic ingredient in RYTARY is carbidopa; levodopa. There are eighteen drug master file entries for this API. Thirty-seven suppliers are listed for this generic product. Additional details are available on the carbidopa; levodopa profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,671,502

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: isavuconazonium sulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 14, 2027
Generic Entry Controlled by: Canada Patent 2,663,941

CRESEMBA is a drug marketed by Astellas. There are three patents protecting this drug.

This drug has thirty-two patent family members in nineteen countries. There has been litigation on patents covering CRESEMBA

See drug price trends for CRESEMBA.

The generic ingredient in CRESEMBA is isavuconazonium sulfate. One supplier is listed for this generic product. Additional details are available on the isavuconazonium sulfate profile page.

Generic name: pirfenidone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,620,380

ESBRIET is a drug marketed by Legacy Pharma. There are twenty patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has two hundred and sixty-six patent family members in forty-six countries. There has been litigation on patents covering ESBRIET

See drug price trends for ESBRIET.

The generic ingredient in ESBRIET is pirfenidone. There are twenty-three drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the pirfenidone profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: Canada Patent 2,664,275

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: olaparib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 17, 2026
Generic Entry Controlled by: Canada Patent 2,875,147

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

Generic name: ixazomib citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 06, 2027
Generic Entry Controlled by: Canada Patent 2,695,082

NINLARO is a drug marketed by Takeda Pharms Usa. There are seven patents protecting this drug.

This drug has one hundred and eighty-seven patent family members in forty-four countries. There has been litigation on patents covering NINLARO

See drug price trends for NINLARO.

The generic ingredient in NINLARO is ixazomib citrate. One supplier is listed for this generic product. Additional details are available on the ixazomib citrate profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 28, 2026
Generic Entry Controlled by: Canada Patent 2,616,580

OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.

This drug has sixty-four patent family members in forty-one countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: crizotinib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 23, 2026
Generic Entry Controlled by: Canada Patent 2,632,283

XALKORI is a drug marketed by Pf Prism Cv. There are three patents protecting this drug.

This drug has one hundred and five patent family members in forty-six countries.

See drug price trends for XALKORI.

The generic ingredient in XALKORI is crizotinib. One supplier is listed for this generic product. Additional details are available on the crizotinib profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: ingenol mebutate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 18, 2026
Generic Entry Controlled by: Canada Patent 2,634,073

PICATO is a drug marketed by Leo Labs. There are twelve patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has thirty-five patent family members in twenty-one countries. There has been litigation on patents covering PICATO

See drug price trends for PICATO.

The generic ingredient in PICATO is ingenol mebutate. There are three drug master file entries for this API. Additional details are available on the ingenol mebutate profile page.

Generic name: flutemetamol f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 30, 2027
Generic Entry Controlled by: Canada Patent 2,694,084

VIZAMYL is a drug marketed by Ge Healthcare. There is one patent protecting this drug.

This drug has twenty-three patent family members in twenty countries.

See drug price trends for VIZAMYL.

The generic ingredient in VIZAMYL is flutemetamol f-18. One supplier is listed for this generic product. Additional details are available on the flutemetamol f-18 profile page.

Generic name: prasterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 10, 2027
Generic Entry Controlled by: Canada Patent 2,820,566

INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug.

This drug has fifty-nine patent family members in thirty-two countries.

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the prasterone profile page.

Generic name: menthol; methyl salicylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 04, 2026
Generic Entry Controlled by: Canada Patent 2,652,220

SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.

Generic name: pasireotide pamoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 24, 2027
Generic Entry Controlled by: Canada Patent 2,683,935

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. One supplier is listed for this generic product. Additional details are available on the pasireotide pamoate profile page.

Generic name: alcaftadine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 31, 2026
Generic Entry Controlled by: Canada Patent 2,648,115

LASTACAFT is a drug marketed by Abbvie. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-six patent family members in thirty countries. There has been litigation on patents covering LASTACAFT

See drug price trends for LASTACAFT.

The generic ingredient in LASTACAFT is alcaftadine. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the alcaftadine profile page.

Generic name: lifitegrast
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 19, 2027
Generic Entry Controlled by: Canada Patent 2,702,984

XIIDRA is a drug marketed by Bausch And Lomb Inc. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-five patent family members in twenty-four countries. There has been litigation on patents covering XIIDRA

See drug price trends for XIIDRA.

The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this generic product. Additional details are available on the lifitegrast profile page.

Generic name: florbetapir f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 26, 2027
Generic Entry Controlled by: Canada Patent 2,644,530

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

Generic name: fluciclovine f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,629,227

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.

This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 20, 2027
Generic Entry Controlled by: Canada Patent 2,638,081

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Canada Patent 2,690,841

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: deoxycholic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: Canada Patent 2,789,109

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and forty-six patent family members in thirty-eight countries. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. There are thirty-three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the deoxycholic acid profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 21, 2026
Generic Entry Controlled by: Canada Patent 2,659,662

RASUVO is a drug marketed by Medexus. There is one patent protecting this drug.

This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: amphetamine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: Canada Patent 2,645,855

DYANAVEL XR is a drug marketed by Tris Pharma Inc. There are eleven patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has twenty-one patent family members in fourteen countries. There has been litigation on patents covering DYANAVEL XR

See drug price trends for DYANAVEL XR.

The generic ingredient in DYANAVEL XR is amphetamine. There are fifty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the amphetamine profile page.

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: Canada Patent 2,671,357

INVOKAMET XR is a drug marketed by Janssen Pharms. There are three patents protecting this drug.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKAMET XR

See drug price trends for INVOKAMET XR.

The generic ingredient in INVOKAMET XR is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

Generic name: mirabegron
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 02, 2027
Generic Entry Controlled by: Canada Patent 2,704,298

MYRBETRIQ is a drug marketed by Apgdi. There are six patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has fifty-three patent family members in twenty-five countries. There has been litigation on patents covering MYRBETRIQ

See drug price trends for MYRBETRIQ.

The generic ingredient in MYRBETRIQ is mirabegron. There are nineteen drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the mirabegron profile page.

Generic name: treprostinil diolamine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 27, 2026
Generic Entry Controlled by: Canada Patent 2,649,243

ORENITRAM is a drug marketed by United Therap. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has fifty-nine patent family members in eight countries. There has been litigation on patents covering ORENITRAM

See drug price trends for ORENITRAM.

The generic ingredient in ORENITRAM is treprostinil diolamine. There are nineteen drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the treprostinil diolamine profile page.

Generic name: hydrocodone bitartrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,663,172

VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.

Generic name: hydrocodone bitartrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 15, 2026
Generic Entry Controlled by: Canada Patent 2,699,142

VANTRELA ER is a drug marketed by Teva Branded Pharm. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has thirty-three patent family members in thirteen countries. There has been litigation on patents covering VANTRELA ER

The generic ingredient in VANTRELA ER is hydrocodone bitartrate. There are twenty-three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the hydrocodone bitartrate profile page.

Generic name: eslicarbazepine acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,616,984

APTIOM is a drug marketed by Sumitomo Pharma Am. There are seven patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety-three patent family members in twenty-six countries. There has been litigation on patents covering APTIOM

See drug price trends for APTIOM.

The generic ingredient in APTIOM is eslicarbazepine acetate. There are twelve drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the eslicarbazepine acetate profile page.

Generic name: suvorexant
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: Canada Patent 2,670,892

BELSOMRA is a drug marketed by Merck Sharp Dohme. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has seventy-five patent family members in thirty-six countries.

See drug price trends for BELSOMRA.

The generic ingredient in BELSOMRA is suvorexant. One supplier is listed for this generic product. Additional details are available on the suvorexant profile page.

Generic name: bosutinib monohydrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,613,053

BOSULIF is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and two Paragraph IV challenges. Three tentatively approved generics are ready to enter the market.

This drug has eighty-one patent family members in thirty countries. There has been litigation on patents covering BOSULIF

See drug price trends for BOSULIF.

The generic ingredient in BOSULIF is bosutinib monohydrate. There are five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bosutinib monohydrate profile page.

Generic name: ticagrelor
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 20, 2027
Generic Entry Controlled by: Canada Patent 2,659,328

BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in thirty-five countries. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. There are twenty-one drug master file entries for this API. Twenty-six suppliers are listed for this generic product. Additional details are available on the ticagrelor profile page.

Generic name: daclatasvir dihydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 08, 2027
Generic Entry Controlled by: Canada Patent 2,695,729

DAKLINZA is a drug marketed by Bristol-myers Squibb. There are five patents protecting this drug.

This drug has ninety-three patent family members in thirty-one countries. There has been litigation on patents covering DAKLINZA

See drug price trends for DAKLINZA.

The generic ingredient in DAKLINZA is daclatasvir dihydrochloride. There are five drug master file entries for this API. Additional details are available on the daclatasvir dihydrochloride profile page.

Generic name: azilsartan kamedoxomil
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 28, 2027
Generic Entry Controlled by: Canada Patent 2,681,143

EDARBI is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has twenty-one patent family members in seventeen countries. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the azilsartan kamedoxomil profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: empagliflozin; linagliptin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Canada Patent 2,696,558

GLYXAMBI is a drug marketed by Boehringer Ingelheim. There are fifteen patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has five hundred and twenty-one patent family members in forty-five countries. There has been litigation on patents covering GLYXAMBI

See drug price trends for GLYXAMBI.

The generic ingredient in GLYXAMBI is empagliflozin; linagliptin. There are twenty-two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the empagliflozin; linagliptin profile page.

Generic name: axitinib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 05, 2027
Generic Entry Controlled by: Canada Patent 2,682,859

INLYTA is a drug marketed by Pf Prism Cv. There are three patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.

Generic name: canagliflozin; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: Canada Patent 2,671,357

INVOKAMET is a drug marketed by Janssen Pharms. There are four patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and seventy-one patent family members in forty-eight countries. There has been litigation on patents covering INVOKAMET

See drug price trends for INVOKAMET.

The generic ingredient in INVOKAMET is canagliflozin; metformin hydrochloride. There are twenty-one drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the canagliflozin; metformin hydrochloride profile page.

Generic name: empagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2027
Generic Entry Controlled by: Canada Patent 2,696,558

JARDIANCE is a drug marketed by Boehringer Ingelheim. There are fifteen patents protecting this drug and one Paragraph IV challenge. Eighteen tentatively approved generics are ready to enter the market.

This drug has four hundred and eighteen patent family members in forty-six countries. There has been litigation on patents covering JARDIANCE

See drug price trends for JARDIANCE.

The generic ingredient in JARDIANCE is empagliflozin. There are twenty-two drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the empagliflozin profile page.

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 19, 2027
Generic Entry Controlled by: Canada Patent 2,694,620

KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

Generic name: ambrisentan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 11, 2027
Generic Entry Controlled by: Canada Patent 2,669,536

LETAIRIS is a drug marketed by Gilead. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in twenty-six countries. There has been litigation on patents covering LETAIRIS

See drug price trends for LETAIRIS.

The generic ingredient in LETAIRIS is ambrisentan. There are nine drug master file entries for this API. Thirteen suppliers are listed for this generic product. Additional details are available on the ambrisentan profile page.

Generic name: alogliptin benzoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,193

NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.

Generic name: macitentan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 28, 2027
Generic Entry Controlled by: Canada Patent 2,659,770

OPSUMIT is a drug marketed by Actelion. There are five patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSUMIT

See drug price trends for OPSUMIT.

The generic ingredient in OPSUMIT is macitentan. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan profile page.

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 01, 2027
Generic Entry Controlled by: Canada Patent 2,677,201

OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has one hundred and one patent family members in forty-two countries. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. There are ten drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

Generic name: eltrombopag olamine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 03, 2027
Generic Entry Controlled by: Canada Patent 2,685,831

PROMACTA is a drug marketed by Novartis. There are six patents protecting this drug and two Paragraph IV challenges.

This drug has one hundred and thirty-five patent family members in forty-one countries. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. There are three drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the eltrombopag olamine profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,653,344

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2026
Generic Entry Controlled by: Canada Patent 2,924,318

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: edoxaban tosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: Canada Patent 2,680,039

SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: Canada Patent 2,668,512

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

Generic name: linagliptin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 04, 2026
Generic Entry Controlled by: Canada Patent 2,649,922

TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 15, 2027
Generic Entry Controlled by: Canada Patent 2,655,212

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

Generic name: vortioxetine hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: Canada Patent 2,684,571

TRINTELLIX is a drug marketed by Takeda Pharms Usa. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and seventeen patent family members in forty-two countries. There has been litigation on patents covering TRINTELLIX

See drug price trends for TRINTELLIX.

The generic ingredient in TRINTELLIX is vortioxetine hydrobromide. There are sixteen drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the vortioxetine hydrobromide profile page.

Generic name: rolapitant hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 22, 2027
Generic Entry Controlled by: Canada Patent 2,681,465

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.

Generic name: safinamide mesylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 08, 2027
Generic Entry Controlled by: Canada Patent 2,653,012

XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug.

This drug has ninety-seven patent family members in thirty-one countries. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the safinamide mesylate profile page.

Generic name: lefamulin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 20, 2027
Generic Entry Controlled by: Canada Patent 2,678,795

XENLETA is a drug marketed by Hong Kong. There are four patents protecting this drug.

This drug has one hundred and twenty patent family members in thirty-six countries. There has been litigation on patents covering XENLETA

See drug price trends for XENLETA.

The generic ingredient in XENLETA is lefamulin acetate. Additional details are available on the lefamulin acetate profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Canada Patent 2,657,347

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: cedazuridine; decitabine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 16, 2027
Generic Entry Controlled by: Canada Patent 2,702,274

INQOVI is a drug marketed by Taiho Oncology. There are six patents protecting this drug.

This drug has ninety-three patent family members in forty-one countries. There has been litigation on patents covering INQOVI

See drug price trends for INQOVI.

The generic ingredient in INQOVI is cedazuridine; decitabine. One supplier is listed for this generic product. Additional details are available on the cedazuridine; decitabine profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Canada Patent 2,688,478

TRELSTAR is a drug marketed by Verity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

See drug price trends for TRELSTAR.

The generic ingredient in TRELSTAR is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 20, 2027
Generic Entry Controlled by: Canada Patent 2,638,081

TRIFERIC AVNU is a drug marketed by Rockwell Medical Inc. There is one patent protecting this drug.

This drug has twelve patent family members in eleven countries.

See drug price trends for TRIFERIC AVNU.

The generic ingredient in TRIFERIC AVNU is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: ethinyl estradiol; levonorgestrel
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: Canada Patent 2,692,884

TWIRLA is a drug marketed by Agile. There are three patents protecting this drug. Two tentatively approved generics are ready to enter the market.

This drug has nineteen patent family members in twelve countries.

See drug price trends for TWIRLA.

The generic ingredient in TWIRLA is ethinyl estradiol; levonorgestrel. There are twenty-six drug master file entries for this API. Twenty-three suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; levonorgestrel profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,691,445

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,871,025

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: clascoterone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 03, 2027
Generic Entry Controlled by: Canada Patent 2,871,039

WINLEVI is a drug marketed by Sun Pharm. There are eight patents protecting this drug.

This drug has ninety-three patent family members in twenty-nine countries. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. One supplier is listed for this generic product. Additional details are available on the clascoterone profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Canada Patent 2,692,867

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: tepotinib hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 12, 2027
Generic Entry Controlled by: Canada Patent 2,693,600

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug.

This drug has seventy-nine patent family members in thirty-six countries. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. One supplier is listed for this generic product. Additional details are available on the tepotinib hydrochloride profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,667,155

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,667,460

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: difelikefalin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: Canada Patent 2,898,514

KORSUVA is a drug marketed by Vifor Intl. There are twelve patents protecting this drug.

This drug has fifty-three patent family members in twenty-seven countries. There has been litigation on patents covering KORSUVA

See drug price trends for KORSUVA.

The generic ingredient in KORSUVA is difelikefalin acetate. One supplier is listed for this generic product. Additional details are available on the difelikefalin acetate profile page.

Generic name: ferric pyrophosphate citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 20, 2026
Generic Entry Controlled by: Canada Patent 2,550,493

TRIFERIC is a drug marketed by Rockwell Medical Inc. There are two patents protecting this drug.

This drug has thirteen patent family members in eleven countries.

See drug price trends for TRIFERIC.

The generic ingredient in TRIFERIC is ferric pyrophosphate citrate. There are twenty drug master file entries for this API. Additional details are available on the ferric pyrophosphate citrate profile page.

Generic name: dapagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,985,797

FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,985,797

QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

Generic name: panobinostat lactate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 07, 2027
Generic Entry Controlled by: Canada Patent 2,650,263

FARYDAK is a drug marketed by Secura. There are two patents protecting this drug.

This drug has sixty-eight patent family members in forty countries. There has been litigation on patents covering FARYDAK

See drug price trends for FARYDAK.

The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this API. Additional details are available on the panobinostat lactate profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: Canada Patent 2,656,456

EPIDUO is a drug marketed by Galderma Labs Lp and Galderma LabsThere are three patents protecting this drug and two Paragraph IV challenges.

This drug has thirty-five patent family members in twenty-two countries. There has been litigation on patents covering EPIDUO

See drug price trends for EPIDUO.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 08, 2026
Generic Entry Controlled by: Canada Patent 2,913,963

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: lifitegrast
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 19, 2027
Generic Entry Controlled by: Canada Patent 3,105,972

XIIDRA is a drug marketed by Bausch And Lomb Inc. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-five patent family members in twenty-four countries. There has been litigation on patents covering XIIDRA

See drug price trends for XIIDRA.

The generic ingredient in XIIDRA is lifitegrast. Three suppliers are listed for this generic product. Additional details are available on the lifitegrast profile page.

Generic name: adapalene; benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: Canada Patent 2,656,456

EPIDUO FORTE is a drug marketed by Galderma Labs. There has been litigation on patents covering EPIDUO FORTE

See drug price trends for EPIDUO FORTE.

The generic ingredient in EPIDUO FORTE is adapalene; benzoyl peroxide. There are twelve drug master file entries for this API. Twelve suppliers are listed for this generic product. Additional details are available on the adapalene; benzoyl peroxide profile page.

Generic name: amlodipine besylate; hydrochlorothiazide; valsartan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,654,986

EXFORGE HCT is a drug marketed by Novartis. There has been litigation on patents covering EXFORGE HCT

See drug price trends for EXFORGE HCT.

The generic ingredient in EXFORGE HCT is amlodipine besylate; hydrochlorothiazide; valsartan. There are fifty drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the amlodipine besylate; hydrochlorothiazide; valsartan profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: Canada Patent 2,985,797

BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 23, 2026
Generic Entry Controlled by: Canada Patent 2,654,872

TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirty-two patent family members in twenty-five countries. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

Generic name: methotrexate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 21, 2026
Generic Entry Controlled by: Canada Patent 2,869,671

RASUVO is a drug marketed by Medexus. There is one patent protecting this drug.

This drug has twenty-nine patent family members in twenty-one countries. There has been litigation on patents covering RASUVO

See drug price trends for RASUVO.

The generic ingredient in RASUVO is methotrexate. There are twenty drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the methotrexate profile page.

Generic name: benzoyl peroxide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 02, 2026
Generic Entry Controlled by: Canada Patent 2,617,681

EPSOLAY is a drug marketed by Mayne Pharma. There are fourteen patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has fifty-one patent family members in fifteen countries. There has been litigation on patents covering EPSOLAY

See drug price trends for EPSOLAY.

The generic ingredient in EPSOLAY is benzoyl peroxide. There are seventeen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the benzoyl peroxide profile page.

Generic name: ganaxolone
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: Canada Patent 2,631,233

ZTALMY is a drug marketed by Marinus. There are eleven patents protecting this drug.

This drug has forty-eight patent family members in sixteen countries. There has been litigation on patents covering ZTALMY

See drug price trends for ZTALMY.

The generic ingredient in ZTALMY is ganaxolone. One supplier is listed for this generic product. Additional details are available on the ganaxolone profile page.

Generic name: telotristat etiprate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: Canada Patent 2,672,233

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

This drug has seventy patent family members in twenty-nine countries.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. One supplier is listed for this generic product. Additional details are available on the telotristat etiprate profile page.

Generic name: gallium ga-68 gozetotide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 17, 2027
Generic Entry Controlled by: Canada Patent 2,696,627

LOCAMETZ is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has fifty-four patent family members in sixteen countries.

See drug price trends for LOCAMETZ.

The generic ingredient in LOCAMETZ is gallium ga-68 gozetotide. There are sixteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the gallium ga-68 gozetotide profile page.

Generic name: aminolevulinic acid hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 22, 2026
Generic Entry Controlled by: Canada Patent 2,670,715

AMELUZ is a drug marketed by Biofrontera. There are three patents protecting this drug.

This drug has thirty-one patent family members in eighteen countries.

See drug price trends for AMELUZ.

The generic ingredient in AMELUZ is aminolevulinic acid hydrochloride. There are six drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Generic name: sotagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 29, 2026
Generic Entry Controlled by: Canada Patent 2,664,688

INPEFA is a drug marketed by Lexicon Pharms Inc. There are three patents protecting this drug.

This drug has eighty-one patent family members in thirty-three countries.

See drug price trends for INPEFA.

The generic ingredient in INPEFA is sotagliflozin. One supplier is listed for this generic product. Additional details are available on the sotagliflozin profile page.

Generic name: vadadustat
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2027
Generic Entry Controlled by: Canada Patent 2,659,682

VAFSEO is a drug marketed by Akebia. There are thirteen patents protecting this drug.

This drug has two hundred and sixty-two patent family members in forty-eight countries. There has been litigation on patents covering VAFSEO

The generic ingredient in VAFSEO is vadadustat. One supplier is listed for this generic product. Additional details are available on the vadadustat profile page.

Generic name: sacubitril; valsartan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: Canada Patent 2,590,511

ENTRESTO SPRINKLE is a drug marketed by Novartis. There are three patents protecting this drug.

This drug has one hundred and eight patent family members in thirty-nine countries. There has been litigation on patents covering ENTRESTO SPRINKLE

See drug price trends for ENTRESTO SPRINKLE.

The generic ingredient in ENTRESTO SPRINKLE is sacubitril; valsartan. There are eleven drug master file entries for this API. Twenty-four suppliers are listed for this generic product. Additional details are available on the sacubitril; valsartan profile page.

Generic name: macitentan; tadalafil
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 28, 2027
Generic Entry Controlled by: Canada Patent 2,659,770

OPSYNVI is a drug marketed by Actelion. There are three patents protecting this drug.

This drug has one hundred patent family members in thirty-five countries. There has been litigation on patents covering OPSYNVI

See drug price trends for OPSYNVI.

The generic ingredient in OPSYNVI is macitentan; tadalafil. There are ten drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the macitentan; tadalafil profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 22, 2026
Generic Entry Controlled by: Canada Patent 2,623,114

ZUNVEYL is a drug marketed by Alpha Cognition. There are three patents protecting this drug.

This drug has twenty-six patent family members in seventeen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 06, 2027
Generic Entry Controlled by: Canada Patent 2,688,478

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-seven patent family members in thirty-two countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: canagliflozin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 03, 2027
Generic Entry Controlled by: Canada Patent 2,671,357

INVOKANA is a drug marketed by Janssen Pharms. There are three patents protecting this drug and one Paragraph IV challenge. Five tentatively approved generics are ready to enter the market.

This drug has two hundred and twenty patent family members in forty-five countries. There has been litigation on patents covering INVOKANA

See drug price trends for INVOKANA.

The generic ingredient in INVOKANA is canagliflozin. There are twenty-one drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the canagliflozin profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,933

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 08, 2026
Generic Entry Controlled by: Canada Patent 2,609,948

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,609,953

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 09, 2026
Generic Entry Controlled by: Canada Patent 2,610,662

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: azelaic acid
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 07, 2026
Generic Entry Controlled by: Canada Patent 2,611,577

FINACEA is a drug marketed by One tentatively approved generic is ready to enter the market.

This drug has one hundred and thirty-seven patent family members in twenty countries. There has been litigation on patents covering FINACEA

See drug price trends for FINACEA .

The generic ingredient in FINACEA is azelaic acid. There are eight drug master file entries for this API. Eight suppliers are listed for this generic product. Additional details are available on the azelaic acid profile page.

Generic name: donepezil hydrochloride; memantine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 06, 2026
Generic Entry Controlled by: Canada Patent 2,604,052

NAMZARIC is a drug marketed by Abbvie. There are two patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has sixty-seven patent family members in nineteen countries. There has been litigation on patents covering NAMZARIC

See drug price trends for NAMZARIC.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,570,755

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: lenalidomide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,972,299

REVLIMID is a drug marketed by Bristol Myers Squibb. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries. There has been litigation on patents covering REVLIMID

See drug price trends for REVLIMID.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this API. Nineteen suppliers are listed for this generic product. Additional details are available on the lenalidomide profile page.

Generic name: boceprevir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 31, 2026
Generic Entry Controlled by: Canada Patent 2,611,155

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

Generic name: lisdexamfetamine dimesylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 10, 2026
Generic Entry Controlled by: Canada Patent 2,603,873

VYVANSE is a drug marketed by Takeda Pharms Usa. There has been litigation on patents covering VYVANSE

See drug price trends for VYVANSE.

The generic ingredient in VYVANSE is lisdexamfetamine dimesylate. Twenty-one suppliers are listed for this generic product. Additional details are available on the lisdexamfetamine dimesylate profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2026
Generic Entry Controlled by: Canada Patent 2,608,436

XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Four tentatively approved generics are ready to enter the market.

This drug has one hundred and ninety-one patent family members in thirty-five countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: enzalutamide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 29, 2027
Generic Entry Controlled by: Canada Patent 2,648,139

XTANDI is a drug marketed by Astellas. There are seven patents protecting this drug and one Paragraph IV challenge. Four tentatively approved generics are ready to enter the market.

This drug has one hundred and ninety-one patent family members in thirty-five countries. There has been litigation on patents covering XTANDI

See drug price trends for XTANDI.

The generic ingredient in XTANDI is enzalutamide. There are nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the enzalutamide profile page.

Generic name: crisaborole
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680

EUCRISA is a drug marketed by Anacor Pharms Inc. There are four patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has one hundred and forty-eight patent family members in twenty-eight countries. There has been litigation on patents covering EUCRISA

See drug price trends for EUCRISA.

The generic ingredient in EUCRISA is crisaborole. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the crisaborole profile page.

Generic name: belinostat
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 11, 2026
Generic Entry Controlled by: Canada Patent 2,606,598

BELEODAQ is a drug marketed by Acrotech Biopharma. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-nine patent family members in twenty-seven countries. There has been litigation on patents covering BELEODAQ

See drug price trends for BELEODAQ.

The generic ingredient in BELEODAQ is belinostat. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the belinostat profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 05, 2026
Generic Entry Controlled by: Canada Patent 2,609,401

OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: tavaborole
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 16, 2026
Generic Entry Controlled by: Canada Patent 2,635,680

KERYDIN is a drug marketed by Anacor Pharms Inc. There has been litigation on patents covering KERYDIN

See drug price trends for KERYDIN.

The generic ingredient in KERYDIN is tavaborole. There are six drug master file entries for this API. Seven suppliers are listed for this generic product. Additional details are available on the tavaborole profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299

LO MINASTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO MINASTRIN FE

The generic ingredient in LO MINASTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2026
Generic Entry Controlled by: Canada Patent 2,578,626

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2027
Generic Entry Controlled by: Canada Patent 2,655,596

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: bosentan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 15, 2026
Generic Entry Controlled by: Canada Patent 2,607,098

TRACLEER is a drug marketed by Actelion. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has twenty-eight patent family members in twenty-three countries. There has been litigation on patents covering TRACLEER

See drug price trends for TRACLEER.

The generic ingredient in TRACLEER is bosentan. There are nineteen drug master file entries for this API. Six suppliers are listed for this generic product. Additional details are available on the bosentan profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 2,619,591

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,763

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 26, 2027
Generic Entry Controlled by: Canada Patent 2,640,974

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 18, 2026
Generic Entry Controlled by: Canada Patent 3,050,453

AURYXIA is a drug marketed by Keryx Biopharms. There are three patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: lurasidone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 26, 2026
Generic Entry Controlled by: Canada Patent 2,606,510

LATUDA is a drug marketed by Sunovion Pharms Inc. There are six patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has forty-four patent family members in twenty-two countries. There has been litigation on patents covering LATUDA

See drug price trends for LATUDA.

The generic ingredient in LATUDA is lurasidone hydrochloride. There are twenty-six drug master file entries for this API. Twenty-nine suppliers are listed for this generic product. Additional details are available on the lurasidone hydrochloride profile page.

Generic name: ethinyl estradiol; norethindrone acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 17, 2026
Generic Entry Controlled by: Canada Patent 2,605,299

LO LOESTRIN FE is a drug marketed by Apil. There is one patent protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has nine patent family members in seven countries. There has been litigation on patents covering LO LOESTRIN FE

See drug price trends for LO LOESTRIN FE.

The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this API. Twenty-five suppliers are listed for this generic product. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Generic name: lapatinib ditosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 18, 2026
Generic Entry Controlled by: Canada Patent 2,606,207

TYKERB is a drug marketed by Novartis. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-eight patent family members in twenty-six countries.

See drug price trends for TYKERB.

The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the lapatinib ditosylate profile page.

Generic name: cenobamate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 21, 2026
Generic Entry Controlled by: Canada Patent 2,606,258

XCOPRI is a drug marketed by Sk Life. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-six patent family members in twenty countries. There has been litigation on patents covering XCOPRI

See drug price trends for XCOPRI.

The generic ingredient in XCOPRI is cenobamate. One supplier is listed for this generic product. Additional details are available on the cenobamate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 14, 2026
Generic Entry Controlled by: Canada Patent 2,604,943

JATENZO is a drug marketed by Tolmar. There are ten patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has twenty-nine patent family members in fourteen countries. There has been litigation on patents covering JATENZO

See drug price trends for JATENZO.

The generic ingredient in JATENZO is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 28, 2026
Generic Entry Controlled by: Canada Patent 2,606,282

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: cabotegravir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 26, 2026
Generic Entry Controlled by: Canada Patent 2,626,956

VOCABRIA is a drug marketed by Viiv Hlthcare. There are two patents protecting this drug.

This drug has one hundred and twenty-six patent family members in thirty-three countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this generic product. Additional details are available on the cabotegravir sodium profile page.

Generic name: belumosudil mesylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 27, 2026
Generic Entry Controlled by: Canada Patent 2,602,254

REZUROCK is a drug marketed by Kadmon Pharms Llc. There are five patents protecting this drug.

This drug has fifty-seven patent family members in twenty-nine countries.

See drug price trends for REZUROCK.

The generic ingredient in REZUROCK is belumosudil mesylate. One supplier is listed for this generic product. Additional details are available on the belumosudil mesylate profile page.

Generic name: abaloparatide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 03, 2026
Generic Entry Controlled by: Canada Patent 2,664,734

TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

Generic name: migalastat hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 16, 2027
Generic Entry Controlled by: Canada Patent 2,652,553

GALAFOLD is a drug marketed by Amicus Therap Us. There are sixty-three patents protecting this drug.

This drug has two hundred and ninety patent family members in thirty-one countries. There has been litigation on patents covering GALAFOLD

The generic ingredient in GALAFOLD is migalastat hydrochloride. One supplier is listed for this generic product. Additional details are available on the migalastat hydrochloride profile page.